FDA found seafood HACCP violations at Hainan Golden Spring Foods, including unsupported drug-residue test records for tilapia.
What happened
FDA inspected the company’s seafood processing facility on December 13 – 15, 2021. It found the firm did not follow its HACCP monitoring and verification procedures for every lot at CCP1 for aquaculture drug residues in raw frozen reduced oxygen packed tilapia fillets. The firm’s January 5, 2022 response included a revised HACCP plan, but FDA found it inadequate because the lab comparison used a single test from a single lot and did not show the test kits could detect drugs at the reported level.
What FDA found
Production records for two 2021 tilapia lots claimed more aquaculture drug-residue tests than the laboratory equipment log supported.
21 CFR 123.6(b), (c)(4), and (c)(6)The laboratory did not keep sample preparation records, so the firm could not explain the test-count discrepancy; employees estimated that only a portion of reported 2020–2021 tests were actually run.
21 CFR 123.6(b), (c)(4), and (c)(6)The revised HACCP plan’s laboratory comparison used only one test from one lot and did not show the test kits could detect aquaculture drugs at the reported level compared with the national standard method.
21 CFR 123.6FDA deemed the raw frozen reduced oxygen packaged tilapia fillets and whole tilapia G&S adulterated because the firm failed to operate under a compliant seafood HACCP plan.
21 U.S.C. § 342(a)(4); 21 CFR 123.6(g)
What FDA wants
FDA asks the company to respond in writing within 15 working days from receipt, outline corrections, and provide documentation such as a revised HACCP plan and five consecutive days of completed monitoring records for five production date codes. If corrections cannot be completed in 15 days, FDA asks for the reason and a timetable.
Who should pay attention
- U.S. importers and distributors of frozen tilapia
- brands and retailers sourcing seafood from Chinese processors
- seafood processors using contract labs for drug-residue testing
This is a summary. Read the original letter on fda.gov.